Yes I agree with your sentiments but at the time there was something amiss in the OTC and I was hoping it wasn't just NVIV.
Ok, so the scaffold is 100% in-house and on-track. Unreal that Bozo Reynolds never bothered to make it clear that they weren't producing it in-house before.
Couldn't agree more. I added 4800 shares at 1.50 and 1.51.
Talk to the wall then.
I have never put anybody on ignore because in a strange way I even like to hear what bashers say. It has some value and may spark a debate. But this is different! I will actually now use the ignore button. Because I have found a truly useless noisemaker whose posts have no merit whatsoever, regardless of whether they're pro or con. I feel sorry for this person though. He should NOT have a brokerage account.
Nuff said. Banished to Ignoreland, the land of ignoramuses.
Sorry... You were one of the the biggest wuss I ever saw in Ihub and now you're still whining. Had no cojones to hold through the difficult period and now you're whining because apparently you panicked and sold. Grow up.Buy in here and ride it up. This will be a great year.
I've got my GERN position all set. Now I will start accumulating this one. I listened to the audio interview with the CEO and yes, a future star. Growing organs, wow!
No Dogscrew, if FDA changes nothing then nothing changes and it is still Napo's default scenario of $2 without the trial results. However the trial would still be on schedule for Q1, so there will be the rise from the speculation - which anybody following this knows that success is to show safety and any improvements are a bonus.
It is great that Astrue is trying to repair the damage caused by Franny. Anyway starting with worst case:
Worst case, the FDA sticks to their plan (for now) and the trials start in Q1 under the same timetable. We are no worse off than Napodano's "worst case" scenario and that is the current pps of about $2.00. Better cases would be resubmission to FDA after the start of the trials and supported by encouraging data. That is still an intermediate possibility.
Better and best case scenarios would be an approval of the proposed modification before the start of the trials. I'm guessing we should know something NO LATER THAN mid January. If this winds up being approved, then we are really no worse off than back in mid summer. The scaffold schedule would be back on course, the hydrogels proceeding with a more pro-active strategy, a better CEO, and we begin a new move toward up-listing. One could even argue that in this situation NVIV is even better off because none of Franny's negatives would be present anymore, and with a more effective and trustworthy CEO.
When this stock was in the mid to upper 5's there were three catalysts that would likely have propelled it to double digits. Each of those three catalysts should surely occur in 2014 and the last of which likely before Q4. So 2014 ought to be a very good year for NVIV and if the bonus factor comes through from FDA sometime over the next ~6 weeks, I don't see how we would avoid at least a doubling from here BEFORE trials start.
Hey Biotech, Tonto, Nathan, great one and tiny float. Looks like great potential for trading and future mega-appreciation! May even have a nice fit with NVIV on chronic phase in several years.
Amazing! The misanthrope is still out there saying the same thing over and over after being refuted by many people. This person definitely has mental issues.